Black Diamond Therapeutics, Inc. (NASDAQ: BDTX) experienced a stock increase of 3.51% to $2.36 during premarket trading on Tuesday, following the announcement of encouraging Phase 2 clinical trial results for its drug silevertinib. This drug targets non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) non-classical mutations, showing potential as a transformative treatment option. The findings will be presented at the ASCO Annual Meeting on May 30, 2026. In its latest earnings report, the company disclosed a first-quarter loss of 16 cents per share, which was better than the anticipated loss of 18 cents. Additionally, research and development expenses decreased to $7 million, down from $10.5 million a year ago, reflecting progress in the silevertinib trial. The company reported holding $118.3 million in cash, which is projected to sustain operations into the second half of 2028. Analysts maintain a Buy rating for BDTX, with price targets ranging from $8.00 to $14.00.